Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q4 FY24 results · Jan–Mar 2024
Sun Pharma Advanced Research Company reported revenue from operations of ₹16.56 crore and net loss of ₹105.79 crore for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 16.56 | — | — | 13.86 | +19.5% |
| Other income | 4.40 | — | — | 6.39 | −31.1% |
| Total income | 20.96 | — | — | 20.25 | +3.5% |
| Profit before tax | (105.41) | — | — | (99.65) | Loss widened |
| Net profit for the period | (105.79) | — | — | (99.65) | Loss widened |
| EPS, basic (₹) | (3.26) | — | — | (3.07) | Loss widened |
| Net margin (%) | -638.8 | — | -719.0 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 16.56 | 47.69 | −65.3% | 13.86 | +19.5% |
| Other income | 4.40 | 10.73 | −59.0% | 6.39 | −31.1% |
| Total income | 20.96 | 58.42 | −64.1% | 20.25 | +3.5% |
| Profit before tax | (106.69) | (81.99) | Loss widened | (99.65) | Loss widened |
| Net profit for the period | (106.69) | (81.99) | Loss widened | (99.65) | Loss widened |
| EPS, basic (₹) | (3.29) | (2.55) | Loss widened | (3.07) | Loss widened |
| Net margin (%) | -644.3 | -171.9 | -719.0 |
Consolidated
- Filed with BSE
- 25 May 2024, 17:06 IST
- Board meeting
- 24 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 May 2024, 17:06 IST
- Board meeting
- 24 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE